お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
955016

新型コロナウイルス感染症 (COVID-19) パンデミック関連製品のイタリア市場 - 2024年までの予測

Italy COVID-19 Pandemic Mitigation Products (COVID-19 Drugs Market, COVID-19 Vaccine Market, PPE, Self-collection Swabs, COVID-19 AI, Personal Protection Gear, Teleradiology, Eye Protection, and More) Market to 2024

出版日: | 発行: Homeland Security Research Corporation (HSRC) | ページ情報: 英文 410 Pages; 210 Tables & Figures | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円
新型コロナウイルス感染症 (COVID-19) パンデミック関連製品のイタリア市場 - 2024年までの予測
出版日: 2020年08月26日
発行: Homeland Security Research Corporation (HSRC)
ページ情報: 英文 410 Pages; 210 Tables & Figures
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

不可欠な医療製品・サービスの必要性を背景に、新しい市場、新型コロナウイルス感染症 (COVID-19) パンデミック関連製品市場が登場しました。イタリアのCOVID-19パンデミック関連製品における2020年~2024年の累積的な市場規模は、860億米ドル (シナリオB) になると予想されています。

パンデミックの将来は予測できないため、当レポートには2つのシナリオが含まれます。

  • 楽観的シナリオ:2021年7月までに、集団予防接種が始まると想定
  • 保守的シナリオ:2024年7月までは、集団予防接種は利用できないと想定

当レポートでは、イタリアのCOVID-19パンデミック関連製品市場について調査分析し、29の製品・サービス別の市場分析、6のエンドユーザー別の市場分析、4の収益源別の市場分析のほか、主要ベンダー37社の最新データについて、体系的な情報を提供しています。

A. 質問への回答:

  • イタリアのCOVID-19の市場規模、2020年~2024年の予測動向
  • 最も魅力的なビジネス機会
  • 顧客がソリューション・サービスを購入する促進要因
  • イタリアのCOVID-19の市場動向
  • 市場の普及率と成長に対する課題

B. イタリアのCOVID-19の市場規模データ:

  • 29の製品・サービス別
  • 6のエンドユーザー市場別
  • 4の収益源市場別

C. 市場部門別の詳細な市場分析フレームワーク:

  • 1. 市場促進要因・阻害要因
  • 2. ビジネス機会
  • 3. SWOT分析
  • 4. 競合分析
  • 5. ビジネス環境
  • 6. 2020年~2024年の市場規模

D. 主要企業37社の最新データ

(企業のプロファイル、最新の年間収益、COVID-19関連活動・製品、連絡先情報を含む)

E. COVID-19パンデミック関連コミュニティ情報源への2,300以上のリンク

F. 掲載ベンダー:450社以上

G. 5つの付録

目次

Title:
Italy COVID-19 Pandemic Mitigation Products
(COVID-19 Drugs Market, COVID-19 Vaccine Market, PPE, Self-collection Swabs, COVID-19 AI, Personal Protection Gear, Teleradiology, Eye Protection, CT, X-Ray, Ultrasound, COVID-19 IT, Telemedicine, PACS, Face Shields, PPE Gowns, Coronavirus Homecare, Mechanical Ventilators, Gloves, E-Health, Robotic PCR Market, Point of Care Antigen Test, PCR Reagents, Face Masks, ICU, Contact Tracing, Sterilization Systems, Point of Care Serologic Test, Polymerase Chain Reaction, Test Kits, Surge Hospitals and More) Market to 2024.

On the backdrop of the need for essential medical products and services, a new market has emerged, the COVID-19 pandemic mitigation products market. This Italy COVID-19 pandemic mitigation cumulative 2020-2024 market is worth $86 Billion (scenario B).

To adhere to our high standards of research, as nobody can forecast the future of the pandemic, we include in the report two scenarios:

  • 1. Optimistic scenario- assumes (among other things) that mass vaccination will commence by July 2021
  • 2. Conservative scenario- assumes (among other things) that no mass vaccination will be available until July 2024

Why trust this report?

  • The team which created this report was led by ex-executives of the medical industry and bio-security experts, who wrote this report with the COVID-19 industry executives in mind
  • As the COVID-19 pandemic knowledge changes all the time, we update the report once a month
  • The team has published since 2006 36 Pandemic related reports
  • Team members exported medical systems & instrumentation to Italy since 1982

Bottom Line: While other COVID-19 reports are written (at best) by MBAs, this report is published by professionals for experts

According to the report:

Italy is one of the countries hardest hit by the coronavirus pandemic. As this report is published, Italy had 244,434 infected and 35,045 fatalities (578 deaths per million). Italy's early casualties served in many ways as a wake-up call to the world regarding the true deadly nature of the pandemic.

Following a long lockdown of millions, Italy is recovering from a first wave of the COVID-19 outbreak, with many sectors gradually returning to normal levels of activity. Factories are restarting production and consumers are beginning to spend again. However, the crisis has had a dramatic and lingering impact on the national economy.

Being in the center of the pandemic in Europe, Italy last month embarked on a gradual loosening of its lockdown provisions. After allowing factories and construction sites to reopen and eateries and bars to offer takeout in early May, later in the month, restaurants, bars, hairdressers and beauticians were given a green light - as long as they observed social distancing and strict hygiene protocols.

Concessions are at the heart of Italy's surfacing from an two-month lockdown.

At least two explanations may explain the hesitation of the government. The PM faces contrasting concerns of new victims on the one hand, and of misery on the other. Italy had more fatalities than other European countries except the UK. But while the Italian economy experienced less than those of France and Spain in Q1 of 2020, the IMF forecasts a dreadful GDP shrinkage, of 9.1%, by the end of 2020.

Italy second problem is the inconsistency with which COVID-19 proliferates. As the controls were alleviated, three zones in the center and south had no new infections. In Lombardy, thousands of individuals tested positive within a week in contrast from Italy's northern economic centers, came the political pressure to lift the restrictions.

Italy's COVID-19 pandemic mitigation products market is driven by the demand for the following:

  • During the deadly surge of the pandemic by early 2020 to the removal of the lockdown, the country's healthcare establishment invested billions to mitigate the next wave of the pandemic
  • Advanced AI and machine learning have a high demand among general practitioners and others who are not coronavirus ICU experts
  • Italian pharma and biotech companies research and development of coronavirus vaccines and medications
  • Italy invests heavily on PCR and serologic tests. Having said that, national health authorities in Italy does not provide regional data for test-confirmed cases of the virus
  • The growing size of coronavirus related information and mounting complications of datasets, and the needs saved by financial resources

and demand for:

  • Serologic Tests
  • COVID-19 Vaccines
  • Ventilators
  • Electronic Contact Tracing
  • Surge Hospitals
  • PPE
  • Invasive ventilators
  • COVID-19 medical imaging services
  • Training of ICU and ER personnel
  • Strategic National Stockpile
  • New ICU beds
  • COVID-19 medications
  • COVID-19 Informatics
  • Pandemic related turnkey manufacturing plants

This 410 -page market report is the most comprehensive review of the Italian COVID-19 market available today. The objective of this report is to provide today's strategic decision-makers with an expert 360-degree, time-sensitive, detailed view of this interconnected market.

The Italy COVID-19 Pandemic Mitigation Products Market - 2020-2024 report presents a thorough market analysis of 29 products & services, 6 end user, 4 revenue source markets. Furthermore, the report provides updated extensive data of 37 key vendors.

Why Buy this Italy COVID-19 Pandemic Mitigation Products Market Report?

A. Questions answered in this report include:

  • What is the Italian COVID-19 Market size and what are the forecast trends during 2020-2024?
  • What are the most attractive business opportunities?
  • What drives the customers to purchase solutions and services?
  • What are the Italian COVID-19 Market trends?
  • What are the challenges to market penetration & growth?

B. Italian COVID-19 market size data is analyzed via 5 independent key perspectives. With a highly fragmented market we address the "money trail" - each dollar spent in the Italian COVID-19 market is analyzed and crosschecked via 3 orthogonal viewpoints:

By 29 Products and Services:

  • 1. COVID-19 Vaccines
  • 2. COVID-19 Drugs
  • 3. PCR Instrumentation & Software
  • 4. PCR Reagents & Consumables
  • 5. Nose & Mouth Swabs
  • 6. Self-collection PCR Test Kits
  • 7. Serologic Test Kits
  • 8. Standoff Thermometry
  • 9. X-Ray, CT & Ultrasound Procedures
  • 10. Wastewater testing
  • 11. PACS & Teleradiology
  • 12. Medical PPE Gowns
  • 13. Medical Gloves
  • 14. Medical Face Masks
  • 15. Medical Face Shields
  • 16. Medical Eye Protection
  • 17. Sterilization: Systems & Consumables
  • 18. AI, Big Data & Machine Learning
  • 19. Homecare IT
  • 20. Contact Tracing Systems & Services
  • 21. E-Health
  • 22. Other Pandemic Related ICT
  • 23. COVID-19 Homecare (Equipment, Software, Services)
  • 24. Ventilators
  • 25. Surge Capacity Hospitals & Surge ICUs
  • 26. Other Intensive Care Modalities
  • 27. Pandemic Related Manufacturing Plants
  • 28. R&D Equipment & Consumables
  • 29. Other Products & Services

By 6 End User Markets:

  • 1. Hospitals and Surge Hospitals
  • 2. Clinical Labs
  • 3. Clinics
  • 4. Emergency Medical Services (EMS)
  • 5. Homecare & Nursing Homes
  • 6. Research Bodies

By 4 Revenue Source Markets:

  • 1. Product Sales
  • 2. Training Services
  • 3. Planning & Consulting
  • 4. Maintenance & Upgrade

C. Detailed market analysis frameworks for each of the market sectors are provided, including:

  • 1. Market drivers & inhibitors
  • 2. Business opportunities
  • 3. SWOT analysis
  • 4. Competitive analysis for each of the products and services that covers:
  • 1. Barriers to Entry
  • 2. Supplier Power
  • 3. Buyer Power
  • 4. Barriers to Substitution.
  • 5. Business environment
  • 6. The 2020-2024 market size

D. The report provides an updated extensive data of the leading 37 companies

(including companies' profile, recent annual revenues, COVID-19 mitigation activities & products and contact information).

E. The report includes over 2300 links to the COVID-19 pandemic mitigation community information sources

F. The report mentions > 450 Vendors including the following:

Moderna, IBM, 3M Company, Philips NV, Johnson & Johnson, Roche, Nvidia Corporation, Thermo Fisher Scientific, Siemens, Toshiba, Google, Samsung Electronics Co, GE Healthcare, Medtronic, MedWhat, MedyMatch, Merck, Metabiota, Micron Technology, Infermedica, Infervision, Inovio Pharmaceuticals, Microsoft Corporation, Mindshare Medical, Morpheo, Pfizer, Philips NV, Maxim Biotech, Honeywell Safety Products, Philips Healthcare, Siemens, Recursion Pharmaceuticals, Fujifilm Holdings Corporation, 3Scan, Abbott , AbCellera, Advenio Technosys, Agfa Healthcare, Agilent Technologies, AiCure, Aindra, Allscripts Healthcare Solutions, Amara Health Analytics, Amazon , analyticsMD, Apixio, Apple, Arterys Inc., Atlas Wearables, Atomwise, Avalon Nutrition VITL, Babylon Health, Bay Labs, Behold.ai, benevolent.ai, BIOBEATS, BlueDot, Bollé Safety, Bullard, Buoy Health, Care Angel Wearables QorQL, Careskore, Clinithink, Cloud Pharmaceuticals, CloudMedx, CureMetrix Mental health Ginger.io, Cyrcadia, Deep 6 AI, Deep Genomics, Dell Technologies Inc., Delta Plus Group, Desktop Genetics Virtual mate Ada Health, DreaMed Diabetes, Dupont, EaglEyeMed, Eli Lilly, Encon Safety Products, Enlitic, EnsoData, Entopsis, Envisagenics Research iCarbonX, ERB Industries Inc., Ergodyne, Essilor of America, Flashback Technologies, Flow Health, Ford, Freenome, Frequency Therapeutics Inc., Gateway Safety Inc., General Motors, General Vision, Gentex Corporation, Gibco, Gilead Sciences, Globavir Biosciences, Healint, Health Fidelity, HealthNextGen, HexArmor, Hindsait, Imagen Technologies, Imagia Cybernetics, Inside DNA, InSilico Medicine, Intel Corporation, Intendu, Invitrogen, Ion Torrent, Ironwear, Jvion, Kapa Biosystems, Keen Eye Technologies, Kimberly-Clark Professional, Lexmark International Inc., LifeGraph, Lucina Health, Lumiata, Lunit, Lytics, Magnea, Maxwell MRI, McKesson Corporation, MCR Safety, Medal, Medalogix, Medasense, MedAware, Niramai Health Analytix, Novarad Corporation, NuMedii, Numerate, Nuritas Pharma Turbine, Oncora Medical, Ovuline, PeerWell, PhysIQ, Precision Health Intelligence, Predible Health, Profility, Proscia, pulseData, Pyramex Safety, Qualaris Healthcare Solutions, Qualcomm Incorporated, Qualcomm Incorporated, Qure.Ai, Radians Inc., Roam Analytics, RxPREDICT, Safety Optical Service Ltd, Sanofi, Saykara, Sellstrom Manufacturing Company (SureWerx), Sense.ly, Sensory Inc., Sigma-Aldrich Corp., Skymind Inc., Vir Biotechnology Inc., VisionAid Inc., WuXi Biologics, Xilinx Inc. and more.

G. Italy COVID-19 market report includes 5 appendices:

  • Appendix 1: Differences & Similarities between Common Flu and Coronavirus
  • Appendix 2: COVID-19 Tests
  • Appendix 3: Abbreviations
  • Appendix 4: Glossary
  • Appendix 5: Bibliography

COVID-19 pandemic mitigation market research team

The team which composed this report brings 43 years of hands on record in the development and commercialization of healthcare products including: antibody antigen identification, E-health, decontamination and biosecurity, PACS, teleradiology, PPE, computerized tomography, ultrasound, electron microscopy, medical devices and more. Our team members bring long term relations with the U.S. FDA and CDC as well as the EU CE and other national medical regulatory agencies.

As early as January 20, 2020 we recruited all our analysts to research the COVID-19 pandemic mitigation related products purchases. We interviewed hundreds of experts, participated in more than 95 conferences and webinars, reviewed more than 1,500 publications and interviewed executives of more than 65 pandemic related companies.

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.